Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia.

摘要

Relapsed/refractory acute myeloid leukemia (AML) is associated with a poor prognosis and a median overall survival of less than 1 year [1]. Allogeneic hematopoietic stem cell transplant (HSCT) remains the standard of care in this setting. For those patients without available donors or with significant contraindications to transplant, therapeutic options are limited. Many of the chemotherapy regimens for relapsed/refractory AML are dose-intensive and cannot be easily applied in heavily pretreated patients.